Memory Medicine

10/18/2026

09/25/2026

Unfortunately another drug fail … never give up the ReCODE protocol research has promising results

In a double-blind, randomized phase 2 trial, the oral O-linked N-acetylglucosaminidase (OGA) inhibitor was evaluated among patients with early symptomatic and evidence of .

Ceperognastat did not demonstrate clinically meaningful benefit over placebo on progression of and functional impairment, with the higher dose group showing greater clinical decline.

Safety assessment showed increased rates of serious and severe adverse events at the higher ceperognastat dose.

https://ja.ma/4d0SaSa

06/23/2026

https://www.facebook.com/photo.php?fbid=1424083196432630&set=a.625299199644371&type=3

💬 Perspective by John Hsiao, MD: diagnosis and treatment have advanced substantially since the unified conceptual framework published in 1976, with major progress in understanding -β and tau proteins as central drivers.

Monoclonal antibodies, including and , robustly clear brain amyloid-β and slow cognitive decline by approximately 30% in early disease, confirming a causal role for amyloid—though these effects remain modest and are limited by amyloid-related imaging abnormalities.

Current enable staging and preclinical diagnosis, and ongoing trials are testing whether early intervention can prevent onset.

https://ja.ma/44hpyPI

05/01/2026

Elevated blood sugar increases your risk of developing Alzheimer’s disease. Here are three ways to help keep your blood sugar low